Guilherme Nader Marta: Our Review On the PI3K/Akt-targeted Agents

Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on X:

“PI3K/Akt-targeted agents entered clinical practice & may soon bring precision oncology to 1st line of Tx for ER+ breast cancer

Out in Critical Reviews in Oncology Hematology (CROH) our review on the activity, biomarkers & toxicities w/ these agents & next steps in the field”

Read further.
Source: Guilherme Nader Marta/X